|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that a combined approach of targeting high-invasive OVCA cells by blocking glutamine's entry into the TCA cycle, along with targeting low-invasive OVCA cells by inhibiting glutamine synthesis and STAT3 may lead to potential therapeutic approaches for treating OVCAs.
|
24799285 |
2014 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin (IL)-6 and Stat3 play key roles in ovarian cancer progression.
|
23536726 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results revealed that the STAT3 decoy ODN inhibited ovarian cancer cell growth and promoted ovarian cancer cell apoptosis in vivo.
|
23828376 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
STAT3 acetylation-induced promoter methylation is associated with downregulation of the ARHI tumor-suppressor gene in ovarian cancer.
|
23604529 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, these findings emphasize the importance of Stat3 in cisplatin resistance in ovarian cancer and provide a further impetus to clinically evaluate biological modifiers that may circumvent cisplatin resistance in patients with chemoresistant ovarian cancer.
|
23962558 |
2013 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Signal transducer and activator of transcription 3 (STAT3) is activated in majority of ovarian tumors and confers resistance to cisplatin treatment in patients with ovarian cancer.
|
22280969 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of this study is to investigate whether the STAT3 inhibitor HO-3867, a novel curcumin analog, has a therapeutic effect on BRCA1-mutated ovarian cancer.
|
22801507 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hyperactive EGFR signaling through Stat3 and the Jak-Stat3 activity together promote ovarian cancer progression to cisplatin resistance and therefore represent targets for preventing the development of cisplatin resistance and the recurrent disease during cisplatin therapy in ovarian cancer.
|
21909139 |
2012 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Activation of the IL-6-Stat3 pathway contributes to tumor cell growth, survival and drug resistance in several cancers, including ovarian cancer.
|
18587580 |
2009 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Constitutively activated signal transducer and activator of transcription 3 (STAT3) plays an important role in the formation of many tumors including ovarian cancer.
|
18535750 |
2008 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
The activation and translocation of pStat3 to the nucleus are frequent events in ovarian carcinoma that are associated with a poor prognosis.
|
17063503 |
2006 |
|
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Stat3 expression in ovarian cancer tissue microarray was evaluated by immunohistochemistry.
|
16951221 |
2006 |
|
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
STAT3 is frequently phosphorylated and activated in breast and ovarian cancers, where cytokines and growth factors up-regulate STAT3 and stimulate proliferation.
|
16061651 |
2005 |
|
Malignant neoplasm of ovary
|
0.400 |
Biomarker
|
disease |
BEFREE |
Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
|
12061840 |
2002 |
|
Malignant neoplasm of ovary
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The relationship of this aberrancy of ovarian carcinoma harboring activated Stat 3 deserves further investigation.
|
11006034 |
2000 |